Tenax Therapeutics Upgraded to Strong-Buy by Leerink Partnrs
| TENX Stock | USD 6.37 0.04 0.62% |
Slightly above 55% of Tenax Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Tenax Therapeutics suggests that many traders are impartial. Tenax Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tenax Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tenax |
Tenax Therapeutics was upgraded by equities researchers at Leerink Partnrs to a strong-buy rating in a research report issued on Thursday, Zacks.com reports. A number of other research analysts also recently issued reports on the stock. StockNews.com began coverage on shares of Tenax Therapeutics in a research report on Thursday,
Read at thelincolnianonline.com
 |
Tenax Therapeutics Fundamental Analysis
We analyze Tenax Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tenax Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tenax Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Tenax Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Tenax Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tenax Therapeutics stock to make a market-neutral strategy. Peer analysis of Tenax Therapeutics could also be used in its relative valuation, which is a method of valuing Tenax Therapeutics by comparing valuation metrics with similar companies.
Peers
Tenax Therapeutics Related Equities
| ENSC | Ensysce Biosciences | 11.00 | ||||
| ZVSA | ZyVersa Therapeutics | 5.19 | ||||
| ALLR | Allarity Therapeutics | 1.94 | ||||
| VRAX | Virax Biolabs | 1.87 | ||||
| UNCY | Unicycive Therapeutics | 1.64 | ||||
| SONN | Sonnet Biotherapeutics | 1.32 | ||||
| REVB | Revelation Biosciences | 2.44 | ||||
| QNRX | Quoin Pharmaceuticals | 3.39 | ||||
| DRMA | Dermata Therapeutics | 4.32 | ||||
| WINT | Windtree Therapeutics | 4.35 | ||||
| ADTX | Aditxt | 7.14 |
Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.